These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 25227799)

  • 21. HSP27 expression levels are associated with the sensitivity of hepatocellular carcinoma cells to 17-allylamino-17-demethoxygeldanamycin.
    Cui Y; Wu W; Zhou Y; Xie Q; Liu T; Jin J; Liu K
    Future Oncol; 2013 Mar; 9(3):411-8. PubMed ID: 23469976
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Hsp90 inhibitor 17-(allylamino)-17-demethoxygeldanamycin increases cisplatin antitumor activity by inducing p53-mediated apoptosis in head and neck cancer.
    Roh JL; Kim EH; Park HB; Park JY
    Cell Death Dis; 2013 Dec; 4(12):e956. PubMed ID: 24336076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
    Beliakoff J; Bagatell R; Paine-Murrieta G; Taylor CW; Lykkesfeldt AE; Whitesell L
    Clin Cancer Res; 2003 Oct; 9(13):4961-71. PubMed ID: 14581371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role for NAD(P)H:quinone oxidoreductase 1 and manganese-dependent superoxide dismutase in 17-(allylamino)-17-demethoxygeldanamycin-induced heat shock protein 90 inhibition in pancreatic cancer cells.
    Siegel D; Shieh B; Yan C; Kepa JK; Ross D
    J Pharmacol Exp Ther; 2011 Mar; 336(3):874-80. PubMed ID: 21156818
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin.
    Maloney A; Clarke PA; Naaby-Hansen S; Stein R; Koopman JO; Akpan A; Yang A; Zvelebil M; Cramer R; Stimson L; Aherne W; Banerji U; Judson I; Sharp S; Powers M; deBilly E; Salmons J; Walton M; Burlingame A; Waterfield M; Workman P
    Cancer Res; 2007 Apr; 67(7):3239-53. PubMed ID: 17409432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells.
    Roforth MM; Tan C
    Anticancer Drugs; 2008 Aug; 19(7):681-8. PubMed ID: 18594209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro study comparing the efficacy of the water-soluble HSP90 inhibitors, 17-AEPGA and 17-DMAG, with that of the non‑water-soluble HSP90 inhibitor, 17-AAG, in breast cancer cell lines.
    Ghadban T; Jessen A; Reeh M; Dibbern JL; Mahner S; Mueller V; Wellner UF; Güngör C; Izbicki JR; Vashist YK
    Int J Mol Med; 2016 Oct; 38(4):1296-302. PubMed ID: 27498942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of thymidine phosphorylase expression by using an HSP90 inhibitor potentiates the cytotoxic effect of cisplatin in non-small-cell lung cancer cells.
    Weng SH; Tseng SC; Huang YC; Chen HJ; Lin YW
    Biochem Pharmacol; 2012 Jul; 84(1):126-36. PubMed ID: 22480737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1.
    Tse AN; Sheikh TN; Alan H; Chou TC; Schwartz GK
    Mol Pharmacol; 2009 Jan; 75(1):124-33. PubMed ID: 18820127
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models.
    Banerji U; Sain N; Sharp SY; Valenti M; Asad Y; Ruddle R; Raynaud F; Walton M; Eccles SA; Judson I; Jackman AL; Workman P
    Cancer Chemother Pharmacol; 2008 Oct; 62(5):769-78. PubMed ID: 18193424
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiosensitization of human vascular endothelial cells through Hsp90 inhibition with 17-N-allilamino-17-demethoxygeldanamycin.
    Kabakov AE; Makarova YM; Malyutina YV
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(3):858-65. PubMed ID: 18410996
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors.
    Tse AN; Klimstra DS; Gonen M; Shah M; Sheikh T; Sikorski R; Carvajal R; Mui J; Tipian C; O'Reilly E; Chung K; Maki R; Lefkowitz R; Brown K; Manova-Todorova K; Wu N; Egorin MJ; Kelsen D; Schwartz GK
    Clin Cancer Res; 2008 Oct; 14(20):6704-11. PubMed ID: 18927314
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lectin, Galactoside-Binding Soluble 3 Binding Protein Promotes 17-N-Allylamino-17-demethoxygeldanamycin Resistance through PI3K/Akt Pathway in Lung Cancer Cell Line.
    Woo JK; Jang JE; Kang JH; Seong JK; Yoon YS; Kim HC; Lee SJ; Oh SH
    Mol Cancer Ther; 2017 Jul; 16(7):1355-1365. PubMed ID: 28336809
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.
    Modi S; Stopeck A; Linden H; Solit D; Chandarlapaty S; Rosen N; D'Andrea G; Dickler M; Moynahan ME; Sugarman S; Ma W; Patil S; Norton L; Hannah AL; Hudis C
    Clin Cancer Res; 2011 Aug; 17(15):5132-9. PubMed ID: 21558407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression.
    Schulz R; Marchenko ND; Holembowski L; Fingerle-Rowson G; Pesic M; Zender L; Dobbelstein M; Moll UM
    J Exp Med; 2012 Feb; 209(2):275-89. PubMed ID: 22271573
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models.
    Chung YL; Troy H; Banerji U; Jackson LE; Walton MI; Stubbs M; Griffiths JR; Judson IR; Leach MO; Workman P; Ronen SM
    J Natl Cancer Inst; 2003 Nov; 95(21):1624-33. PubMed ID: 14600095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MEK inhibition potentiates the activity of Hsp90 inhibitor 17-AAG against pancreatic cancer cells.
    Zhang T; Li Y; Zhu Z; Gu M; Newman B; Sun D
    Mol Pharm; 2010 Oct; 7(5):1576-84. PubMed ID: 20669973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Topically Applied Hsp90 Blocker 17AAG Inhibits Autoantibody-Mediated Blister-Inducing Cutaneous Inflammation.
    Tukaj S; Bieber K; Kleszczyński K; Witte M; Cames R; Kalies K; Zillikens D; Ludwig RJ; Fischer TW; Kasperkiewicz M
    J Invest Dermatol; 2017 Feb; 137(2):341-349. PubMed ID: 27659253
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of mesoporous silica nanoparticles co‑loading with 17‑AAG and Torin2 on anaplastic thyroid carcinoma by targeting VEGFR2.
    Wang C; Zhang R; Tan J; Meng Z; Zhang Y; Li N; Wang H; Chang J; Wang R
    Oncol Rep; 2020 May; 43(5):1491-1502. PubMed ID: 32323855
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells.
    Kurashina R; Ohyashiki JH; Kobayashi C; Hamamura R; Zhang Y; Hirano T; Ohyashiki K
    Cancer Lett; 2009 Oct; 284(1):62-70. PubMed ID: 19464103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.